<DOC>
	<DOC>NCT00646529</DOC>
	<brief_summary>The purpose of this study is to assess the safety of Symbicort compared to Pulmicort in asthmatic children aged 6 to 11 years</brief_summary>
	<brief_title>Long-Term Safety of Symbicort in Asthmatic Children - SAPLING</brief_title>
	<detailed_description />
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>At least 6 and maximally 11 years of age Diagnosis of asthma Baseline lung function tests as determined by protocol and required and received daily treatment with inhaled corticosteroids for at least 4 weeks prior to study start Has required treatment with any noninhaled corticosteroids within the previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with betablockers Has had cancer in the previous 5 years or has a significant disease that may put the patient at risk in this study</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>asthma</keyword>
	<keyword>children</keyword>
	<keyword>Symbicort</keyword>
	<keyword>budesonide/formoterol</keyword>
	<keyword>Pulmicort</keyword>
	<keyword>budesonide</keyword>
</DOC>